Role Staff Location Zuckerberg San Francisco General Hospital Category Research Education Ph.D., 06/1989 - Biochemistry, Tufts UniversityBSc(Hons), 6/1980 - Chemistry, University of Southampton Publications Disinfection of needleless connectors for catheters in one second using a hand-held UV device. Fourkas M, Takami E, Schears GJ, Farr-Jones S, Rasooly J A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice. Fan Y, Lou J, Tam CC, Wen W, Conrad F, Leal da Silva Alves P, Cheng LW, Garcia-Rodriguez C, Farr-Jones S, Marks JD Multicolor fluorescence activated cell sorting to generate humanized monoclonal antibody binding seven subtypes of BoNT/F. Fan Y, Sun Z, Conrad F, Wen W, Zhao L, Lou J, Zhou Y, Farr-Jones S, Marks JD Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model. Tomic MT, Farr-Jones S, Syar ES, Niemuth N, Kobs D, Hackett MJ, Espinoza Y, Martinez Z, Pham K, Snow DM, Marks JD, Cobb RR A Four-Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotypes C and D. Garcia-Rodriguez C, Yan S, Geren IN, Knopp KA, Dong J, Sun Z, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD Identification of recombinant Fabs for structural and functional characterization of HIV-host factor complexes. Sevillano N, Green EM, Votteler J, Kim DY, Ren X, Yang B, Liu X, Lourenço AL, Hurley JH, Farr-Jones S, Gross JD, Cheng Y, Craik CS A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model. Snow DM, Cobb RR, Martinez J, Finger-Baker I, Collins L, Terpening S, Syar ES, Niemuth N, Kobs D, Barnewall R, Farr-Jones S, Marks JD, Tomic MT Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer. Harel ET, Drake PM, Barfield RM, Lui I, Farr-Jones S, Van't Veer L, Gartner ZJ, Green EM, Lourenço AL, Cheng Y, Hann BC, Rabuka D, Craik CS Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats. Espinoza Y, Wong D, Ahene A, Der K, Martinez Z, Pham J, Cobb RR, Farr-Jones S, Marks JD, Tomic MT Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. Tomic MT, Espinoza Y, Martinez Z, Pham K, Cobb RR, Snow DM, Earnhart CG, Pals T, Syar ES, Niemuth N, Kobs DJ, Farr-Jones S, Marks JD An ambient temperature-stable antitoxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E. Li M, Lee D, Obi CR, Freeberg JK, Farr-Jones S, Tomic MT Antibody engineering to improve manufacturability. Wijesuriya SD, Pongo E, Tomic M, Zhang F, Garcia-Rodriquez C, Conrad F, Farr-Jones S, Marks JD, Horwitz AH A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes. Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. Lou J, Wen W, Conrad F, Meng Q, Dong J, Sun Z, Garcia-Rodriguez C, Farr-Jones S, Cheng LW, Henderson TD, Brown JL, Smith TJ, Smith LA, Cormier A, Marks JD Discovery of internalizing antibodies to basal breast cancer cells. Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD High-throughput screening: update on practices and success. Fox S, Farr-Jones S, Sopchak L, Boggs A, Nicely HW, Khoury R, Biros M High-throughput screening: searching for higher productivity. Fox S, Farr-Jones S, Sopchak L, Boggs A, Comley J High throughput screening 2002: moving toward increased success rates. Fox S, Wang H, Sopchak L, Farr-Jones S Business and science of proteomics--third annual event. Next-generation technologies for high-throughput proteomics. Farr-Jones S The Internet for nuclear magnetic resonance spectroscopists. Avizonis D, Farr-Jones S Chemokine antagonists as anti-inflammatory and antiviral agents II. Farr-Jones S Solution structure of Syrian hamster prion protein rPrP(90-231). Liu H, Farr-Jones S, Ulyanov NB, Llinas M, Marqusee S, Groth D, Cohen FE, Prusiner SB, James TL High Throughput Screening for Drug Discovery: Continually Transitioning into New Technology. Fox S, Farr-Jones S, Yund MA NMR determination of the major solution conformation of a peptoid pentamer with chiral side chains. Armand P, Kirshenbaum K, Goldsmith RA, Farr-Jones S, Barron AE, Truong KT, Dill KA, Mierke DF, Cohen FE, Zuckermann RN, Bradley EK Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. James TL, Liu H, Ulyanov NB, Farr-Jones S, Zhang H, Donne DG, Kaneko K, Groth D, Mehlhorn I, Prusiner SB, Cohen FE Solution structure of omega-conotoxin MVIIC, a high affinity ligand of P-type calcium channels, using 1H NMR spectroscopy and complete relaxation matrix analysis. Farr-Jones S, Miljanich GP, Nadasdi L, Ramachandran J, Basus VJ Converting trypsin to chymotrypsin: ground-state binding does not determine substrate specificity. Hedstrom L, Farr-Jones S, Kettner CA, Rutter WJ Crystal versus solution structure of enzymes: NMR spectroscopy of a peptide boronic acid-serine protease complex in the crystalline state. Farr-Jones S, Smith SO, Kettner CA, Griffin RG, Bachovchin WW Crystal versus solution structures of enzymes: NMR spectroscopy of a crystalline serine protease. Smith SO, Farr-Jones S, Griffin RG, Bachovchin WW Nitrogen-15 NMR spectroscopy of the catalytic-triad histidine of a serine protease in peptide boronic acid inhibitor complexes. Bachovchin WW, Wong WY, Farr-Jones S, Shenvi AB, Kettner CA
